Scout Diagnostics, a company targeting early diagnosis of Alzheimer’s disease, recently received matching funds of $435,600 to support developing a laboratory test to detect and confirm Alzheimer’s disease in its earliest stages. Scout was formed in 2006 by University of Kentucky chemistry professors and Sanders-Brown Center on Aging researchers Mark Lovell and Bert Lynn, along with CEO John Beran.
In a seven-minute video, available for viewing on the University of Kentucky's YouTube channel, Gregory A. Jicha, M.D., Ph.D. narrates the spinal fluid donation procedure as it is performed on him. Other researchers from the Sanders-Brown Center on Aging join Jicha in providing facts about Alzheimer's disease and the importance of spinal fluid in Alzheimer's research.
Dr. Peter Nelson of the University of Kentucky Sanders-Brown is the lead author on a paper published in the journal BRAIN; the paper deals with the little-understood but serious condition hippocampal sclerosis (HS-AGING). He is also the recipient of a newly approved grant from the National Institutes of Health (NIH) to conduct a study of HS-AGING genetics.
Linda J. Van Eldik, director of the University of Kentucky Sanders-Brown Center on Aging, has been awarded a $750,000 grant to further her research into a possible treatment for Alzheimer's Disease. The grant is from the Edward N. And Della L. Thome Memorial Foundation, and is one of only eight Awards in Alzheimer's Disease Drug Discovery Research to be given in the U.S. in 2010.
On January 4, 2011, the National Alzheimer’s Project Act (NAPA) was signed into law by the President of the United States after having been passed unanimously in both the Senate and House of Representatives. This legislation is key to providing the resources and support needed to continue to fight this debilitating disease that affects more than 5 million Americans.
The Alzheimer's Association has created a helpful document which highlights the NAPA. To view their fact sheet, click here.
Scientists at the University of Kentucky have discovered that plasminogen, a protein used by the body to break up blood clots, speeds up the progress of prion diseases such as mad cow disease. This finding makes plasminogen a promising new target for the development of drugs to treat prion diseases in humans and animals, says study senior author Chongsuk Ryou, a researcher at the UK Sanders-Brown Center on Aging and professor of microbiology, immunology, and molecular genetics in the UK College of Medicine.